Interestingly, recent research has provided evidence that both treatment with Entinostat or AACOCF3 can promote antitumor immune responses and overcome resistance to PD-1/PD-L1 blockade in breast, lung, and sarcoma tumors 29, 44-46, indicating targeting NUSAP1 may not only inhibit tumor growth but also enhance tumor immunotherapy. Here, PDCD1 is linked to neoplasm.